PTC of­fers its best case for a con­tro­ver­sial Duchenne MD PhI­II. But key fail­ures spark fresh doubts of suc­cess at FDA

PTC Ther­a­peu­tics’ years-long ef­fort to push its con­tro­ver­sial Duchenne MD drug Translar­na in­to the US has just run in­to its lat­est set­back.

The biotech re­port­ed …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER